Longboard Pharmaceuticals (LBPH)
(Delayed Data from NSDQ)
$34.32 USD
+1.05 (3.16%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $34.32 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth D Momentum F VGM
Income Statements
Fiscal Year end for Longboard Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 57 | 45 | 28 | 14 | 0 |
Income After Depreciation & Amortization | -57 | -45 | -28 | -14 | 0 |
Non-Operating Income | 2 | 1 | 0 | 0 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -54 | -44 | -28 | -14 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -54 | -44 | -28 | -14 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -54 | -44 | -28 | -14 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -57 | -45 | -28 | -14 | 0 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | NA |
Income After Depreciation & Amortization | -57 | -45 | -28 | -14 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 22.73 | 17.15 | 14.41 | NA | NA |
Diluted EPS Before Non-Recurring Items | -2.39 | -2.56 | -1.93 | NA | NA |
Diluted Net EPS (GAAP) | -2.39 | -2.56 | -1.93 | -3.78 | NA |
Fiscal Year end for Longboard Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 25.65 | 18.11 | 15.58 | 13.58 | 15.65 |
Income After SG&A, R&D, and Dept/Amort Expenses | -25.65 | -18.11 | -15.58 | -13.58 | -15.65 |
Non-Operating Income | 3.86 | 3.12 | 0.54 | 0.65 | 0.64 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -21.79 | -14.99 | -15.03 | -12.93 | -15.00 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -21.79 | -14.99 | -15.03 | -12.93 | -15.00 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -21.79 | -14.99 | -15.03 | -12.93 | -15.00 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 38.88 | 35.32 | 24.25 | 23.49 | 22.97 |
Diluted EPS Before Non-Recurring Items | -0.56 | -0.42 | -0.62 | -0.55 | -0.65 |
Diluted Net EPS (GAAP) | -0.56 | -0.42 | -0.63 | -0.55 | -0.65 |